The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Abramowski, Pierre ^a   Otto, Benjamin ^a   Martin, Roland ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EDELFOSINE; GAMMA INTERFERON; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTOME; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOKINE; ETHER PHOSPHOLIPID; MESSENGER RNA;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL DEATH; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; GENE CONTROL; GENE INDUCTION; GENETIC TRANSCRIPTION; GENOME; HUMAN; HUMAN CELL; IMMUNOMODULATION; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PROTEIN PROCESSING; UPREGULATION; CELL CULTURE; CELL PROLIFERATION; DNA MICROARRAY; DRUG EFFECTS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE I; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOLIPID ETHERS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84899790499     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091970     Document Type: Article

References (57)

1. Kny G (1969) Über Lysolecithin-Analoga - Synthese und biologische Eigenschaften.
2. Andreesen R, Modolell M, Weltzien HU, Munder PG (1980) Alkyl-lysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts. Immunobiology 156: 498-508.
3. Mollinedo F, Martínez-Dalmau R, Modolell M (1993) Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. Biochem Biophys Res Commun 192: 603-609.
4. Cabaner C, Gajate C, Macho A, Munoz E, Modolell M, et al. (1999) Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: Involvement of the Fas receptor/ligand system. Br J Pharmacol: 813-825. (Pubitemid 29295339)
5. Gajate C, Del Canto-Jañez E, Acuña AU, Amat-Guerri F, Geijo E, et al. (2004) Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 200: 353-365. (Pubitemid 39031254)
6. Gajate C, Gonzalez-Camacho F, Mollinedo F (2009) Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One 4: e5044.
7. Boggs KP, Rock CO, Jackowski S (1995) Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem 270: 7757-7764.
8. Van der Luit AH, Budde M, Ruurs P, Verheij M, van Blitterswijk WJ (2002) Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 277: 39541-39547. (Pubitemid 35190932)
9. Boggs KP, Rock CO, Jackowski S (1995) Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O- methyl-rac-glycero-3- phosphocholine. J Biol Chem 270: 11612-11618.
10. Mollinedo F, Fernández-Luna JL, Gajate C, Martín- Martín B, Benito A, et al. (1997) Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res 57: 1320-1328. (Pubitemid 27152558)
11. Zerp SF, Vink SR, Ruiter GA, Koolwijk P, Peters E, et al. (2008) Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents. Anticancer Drugs 19: 65-75. (Pubitemid 350190969)
12. Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683-747. (Pubitemid 40563183)
13. Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
14. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A, et al. (1973) Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 2: 1221-1225.
15. Haines JL, Terwedow HA, Burgess K, Pericak-Vance MA, Rimmler JB, et al. (1998) Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet 7: 1229-1234. (Pubitemid 28383054)
16. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallström E, et al. (2007) Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 39: 1108-1113. (Pubitemid 47340654)
17. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, et al. (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851-862. (Pubitemid 47347319)
18. Mohme M, Hotz C, Stevanovic S, Binder T, Lee J-H, et al. (2013) HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. Brain 136: 1783-1798.
19. Lünemann JD, Jelcić I, Roberts S, Lutterotti A, Tackenberg B, et al. (2008) EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 205: 1763-1773.
20. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296: 2832-2838. (Pubitemid 44969183)
21. Riise T, Nortvedt MW, Ascherio A (2003) Smoking is a risk factor for multiple sclerosis. Neurology 61: 1122-1124. (Pubitemid 37461949)
22. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD (1995) Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182: 75-85.
23. Gajate C, Santos-Beneit A, Modolell M, Mollinedo F (1998) Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Mol Pharmacol 53: 602-612. (Pubitemid 28196481)
24. Van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, et al. (2007) A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 6: 2337-2345. (Pubitemid 47294762)
25. Klein-Franke A, Munder PG (1992) Alkyllysophospholipid prevents induction of experimental allergic encephalomyelitis. J Autoimmun 5: 83-91.
26. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
27. Serrano-Fernández P, Möller S, Goertsches R, Fiedler H, Koczan D, et al. (2010) Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 43: 172-178.
28. Jones JL, Thompson SAJ, Loh P, Davies JL, Tuohy OC, et al. (2013) Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A 110: 20200-20205.
29. Munder PG, Westphal O (1990) Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem Immunol 49: 206-235.
30. Fujiwara K, Daniel LW, Modest EJ, Wallen CA (1994) Relationship of cell survival, drug dose, and drug uptake after 1-O-octadecyl-2-O-methyl-rac-glycero- 3-phosphocholine treatment. Cancer Chemother Pharmacol 34: 472-476. (Pubitemid 24306045)
31. Takeda S, Rodewald HR, Arakawa H, Bluethmann H, Shimizu T (1996) MHC class II molecules are not required for survival of newly generated CD4+ T cells, but affect their long-term life span. Immunity 5: 217-228. (Pubitemid 26341365)
32. Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, et al. (2001) IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A 98: 8732-8737. (Pubitemid 32678096)
33. Ernst B, Lee DS, Chang JM, Sprent J, Surh CD (1999) The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 11: 173-181. (Pubitemid 29428810)
34. Sprent J, Surh CD (2011) Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol 12: 478-484.
35. Kondo T, Cortese I, Markovic-Plese S, Wandinger KP, Carter C, et al. (2001) Dendritic cells signal T cells in the absence of exogenous antigen. Nat Immunol 2: 932-938. (Pubitemid 32976165)
36. Revy P, Sospedra M, Barbour B, Trautmann A (2001) Functional antigen-independent synapses formed between T cells and dendritic cells. Nat Immunol 2: 925-931. (Pubitemid 32976164)
37. Laplaud D-A, Ruiz C, Wiertlewski S, Brouard S, Berthelot L, et al. (2004) Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain 127: 981-995. (Pubitemid 38623036)
38. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, et al. (1995) Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3: 407-415.
39. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, et al. (2013) Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci 16: 273-280.
40. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. (2013) Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet.
41. Roos G, Berdel WE (1986) Sensitivity of human hematopoietic cell lines to an alkyl-lysophospholipid-derivative. Leuk Res 10: 195-202. (Pubitemid 16187024)
42. Mollinedo F, Gajate C, Martín-Santamaría S, Gago F (2004) ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem 11: 3163-3184. (Pubitemid 39539180)
43. Kiss Z, Crilly KS (1997) Alkyl lysophospholipids inhibit phorbol ester-stimulated phospholipase D activity and DNA synthesis in fibroblasts. FEBS Lett 412: 313-317. (Pubitemid 27321273)
44. Brinkmann V, Geiger T, Alkan S, Heusser CH (1993) Interferon a increases the frequency of interferon y-producing human CD4 + T cells. J Exp Med 178: 1655-1663. (Pubitemid 23318444)
45. Cousens BLP, Peterson R, Hsu S, Dorner A, Altman JD, et al. (1999) Two roads diverged: interferon a/b- and interleukin 12-mediated pathways in promoting T cell interferon g responses during viral infection. J Exp Med 189: 1315-1327. (Pubitemid 29198269)
46. Van Baarsen LGM, Vosslamber S, Tijssen M, Baggen JMC, van der Voort LF, et al. (2008) Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3: e1927.
47. Sellebjerg F, Datta P, Larsen J, Rieneck K, Alsing I, et al. (2008) Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 14: 615-621. (Pubitemid 351954403)
48. Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, et al. (2008) Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. J Neuroimmunol 199: 115-125.
49. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, et al. (2007) Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 258: 52-59. (Pubitemid 46874477)
50. Muraro PA, Liberati L, Bonanni L, Pantalone A, Caporale CM, et al. (2004) Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol 150: 123-131. (Pubitemid 38481655)
51. Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, et al. (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126: 1419-1429. (Pubitemid 36644386)
52. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, et al. (1997) Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89: 957-964. (Pubitemid 27121289)
53. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523. (Pubitemid 36975769)
54. Chawla-Sarkar M, Leaman DW, Borden EC (2001) Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7: 1821-1831. (Pubitemid 32708654)
55. Micali OC, Cheung HH, Plenchette S, Hurley SL, Liston P, et al. (2007) Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta. BMC Cancer 7: 52.
56. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, et al. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609.
57. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ (2001) Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci U S A 98: 13884-13888. (Pubitemid 33115993)